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Abstract
Background: The value of cardiac troponin as a risk assessment tool for cardiac disease in the setting of end-stage
renal diseases (ESRD) is not equivalent to its value in those with normal renal function. This consideration had not
been studied in settings of acute kidney injury (AKI). We aim to explore the diagnostic value of high sensitive
troponin T (hsTnT) in the settings of cardiac surgery-induced AKI.
Methods: Single center observational retrospective study. Based on the AKI Network, patients divided into 2
groups, group I without AKI (259 patients) and group II with AKI (100 patients) where serial testing of hsTnT
and creatine kinase (CK)-MB were followed in both groups. Patients with (ESRD) were excluded.
Results: The mean age in our study was 55.1 ± 10.2 years. High association of AKI (27.8%) was found in our
patients. Both groups were matched regarding the age, gender, body mass index, the association of diabetes or
hypertension, and Euro score. AKI group had significantly higher mortality 5% vs group I 1.1% (p = 0.03). The hsTnt
showed a significant sustained rise in the AKI group as compared to the non-AKI group, however CK-MB changes
were significant initially but not sustained.
The AKI group was more associated with heart failure 17.9% vs 4.9% (p = 0.001); and post-operative atrial
fibrillation, 12.4% vs 2.9% (p = 0.005). Lengths of ventilation, stays in ICU and in hospital were significantly
higher in the AKI group.
Conclusions: Unlike the CK-MB profile, the hsTnT showed significant changes between both groups all over the
course denoting possible delayed clearance in patients with AKI.
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Background
The ultimate role of cardiac biomarkers in cardiac surgery
remains unresolved, but such biomarkers are currently
used in international guidelines to monitor and define
myocardial infarction. The ideal analytical infrastructure
and target proteins should be highly sensitive for early and
late diagnosis, highly specific, easy to use, and affordable.
These proteins should improve patient outcomes and im-
pact therapeutic modalities [1]. Three subunits form the
backbone of the troponin complex. The C, I and T sub-
units have been studied previously and are located on the
myofibrillar thin (actin) filament of striated (skeletal and
cardiac) muscle. Cardiac muscle expresses the isoforms
troponin T and I, and cardiac troponin T (cTnT) and I
(cTnI) are more specific than creatine kinase (CK) values
for myocardial injury. Thus, these proteins may be ele-
vated when CK-MB is not [2].
The risk assessment of cardiac troponin and other
cardiac biomarkers in end-stage renal disease and
normal renal function is not equivalent. Clinical deci-
sion making based on cardiac biomarkers in patients
with renal diseases requires justification in relation to
patient management or outcomes [3].
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A wide variety of causes may be associated with in-
creases in cardiac enzymes after surgery, including acute
coronary syndrome (ACS) related to recent acute myo-
cardial infarction (AMI) before surgery [4] or periopera-
tive myocardial infarction (PMI) directly related to
cardiac surgery. These enzymes may also be elevated
due to incomplete cardio-protection, reperfusion injury,
and direct surgical trauma [5]. Elevation during cardiac
surgery may not be ACS-related because such elevations
may be caused by end-stage renal disease [6], acute peri-
carditis [7], acute heart failure (AHF), sepsis [8] and
rhabdomyolysis [9].
PMI has a variable incidence and is reported after
coronary artery bypass surgery (CABG) [10]. This
phenomenon occurs both on and off pump, as well as
in valvular surgeries, although it is relatively unusual.
The reported incidence is up to 5% after CABG and 4%
after valvular surgeries [11, 12].
The recently introduced high-sensitivity troponin T
(hsTnT) showed higher sensitivity and negative predict-
ive values than conventional cTn [13]. This marker ex-
hibits excellent diagnostic performance, even with early
presentation to the emergency department in the AMI
scenario [14]. There is some evidence that hsTnT may
possess better diagnostic accuracy than cTn [15]. hsTnT
was introduced in 2010 and has been available at Hamad
Hospital since June 2011. This protein not only serves as
a sensitive and rapid diagnostic tool but may also aid in
short- and long-term mortality prediction.
Cardiac troponin is related to short- and long-term
mortality in the setting of cardiac surgery [16]. PMI is
diagnosed based on a CK-MB increase of more than 10-
fold (99th percentile upper reference level) in combin-
ation with electrocardiogram (ECG), echocardiographic
or angiographic evidence [17]. Acute kidney injury (AKI)
is a frequent complication after cardiac surgery, with a
reported incidence of up to 30%. Renal insufficiency and
acute cerebral events were associated with hsTnT eleva-
tion in the emergency department in a cross-sectional
study performed by Lindner et al. [18].
No previous studies highlighted the influence of
AKI on cardiac hsTnT. In a recent study performed
by Prowle and Kirwan, the authors reported that
long-term outcomes could be influenced after AKI in
cardiac surgery, but cardiac troponins must be studied
in these settings [19]. We hypothesize that hsTnT
could be subjected to changes in the settings of AKI
after cardiac surgery.
Aim of the work
Our goal was to explore the diagnostic value of hsTnT
in the setting of cardiac surgery-induced AKI (with or
without cardiac events).
Methods
1. Study design and assessments
This study was a single-center retrospective
observational study that was conducted over
18 months (March 2011 to September 2013) in a
12-bed cardiothoracic ICU at Hamad Medical
Corporation in Doha, Qatar. The ethical committee
approved the study (reference number 15068/15),
and written informed consent was waived for all
subjects. We excluded patients with sepsis, preexisting
high levels of hsTnT, end-stage renal disease (ESRD),
and AKI before the surgery, as well as patients with
marked intraoperative hypotension (mean arterial
blood pressure less than 33% of the initial value for
more than 10 min) [20]. A total of 19 patients were
excluded. We recruited 359 consecutive patients who
underwent cardiac surgery. The sample size was
calculated to be a minimum of 320 subjects [21].
The following data were recorded for all patients:
age, sex, existence of diabetes or hypertension,
surgery type, length of anesthesia, cardiopulmonary
bypass (CPB) time, aortic cross clamp (ACC) time,
use of vasopressors and inotropes, and Euro SCORE.
Outcome variables, including the length of
mechanical ventilation (LOV), the length of stay in
the ICU (LOSICU) and the length of stay in the
hospital (LOShosp), were recorded. Routine liver
and renal functions were recorded. Complications,
including AKI, post-operative atrial fibrillation
(POAF), infection, stroke, and in-hospital mortality,
were recorded for each patient. Dendrite Clinical
Systems (London, UK) was used to retrieve data.
Blood samples for hsTnT and CK-MB measurements
were collected every six hours for the first 24 h after
surgery and according to clinical indications after
the first 24 h. hsTnT was measured using COBAS
Troponin T hs (highly sensitive) on a STAT (short
turn-around time) instrument (Roche Diagnostics).
ECGs were performed routinely before and
immediately after surgery and every 12 h after
surgery. Transthoracic echocardiography was
performed for all patients before surgery and was
then requested when indicated to trace new regional
wall motion abnormalities in patients with high levels
of cardiac enzymes and in patients requiring high
doses of inotropes.
2. Outcome definitions
The primary outcome was association of hsTnT
with post cardiac surgery AKI, the later was defined
according to the consensus definition proposed by
the Acute Kidney Injury Network. Here, AKI was
defined as an abrupt (within 48 h) reduction in
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kidney function, which was defined as an absolute
increase in the serum creatinine concentration of
0.3 mg/dL or greater (26.4 μmol/L) or a percentage
increase of 50% or greater (1.5-fold from baseline)
[22]. The secondary outcome measures were the
length of mechanical ventilation (LOV), the
LOSICU, and the length of hospitalization. The
patients were divided into two groups based on
AKI status: Group I experienced no AKI, and
Group II experienced AKI.
3. Normally distributed continuous variables were
expressed as the mean ± standard deviation (SD).
Skewed variables were presented as the median
(interquartile range (IQR). The patients were divided
into two groups based on the existence of AKI.
Continuous variables were compared using the
Student’s t-test and the MannWhitney U test, as
appropriate. Chi-square or Fisher’s exact tests were
used to compare categorical variables between the
two groups. A significant association was defined by
a probability (P) value ≤ 0.05 (two-tailed). HsTnT
was converted to natural logarithm values for the
purpose of multivariate linear regression analysis.
Linear multivariate analysis putting the outcome
variables was done in relation to HsTnT, Statistical
analysis was performed using the SPSS software
(version 22, Chicago, IL, USA).
Results
Of the 378 patients screened, 359 patients were enrolled in
the study; the remaining 19 patients met one or more of
the exclusion criteria. Males were predominant in the
study population of 303 patients (84.9%). The mean age
was 57.2 ± 11.6 years, and the majority of patients under-
went CABG surgery (291 patients (82.6%); Tables 1 and 2).
The patients were divided into two groups based on
the existence of AKI. Group I consisted of patients with
no AKI, and Group II consisted of patients with AKI
(Tables 2 and 3). The two groups were well matched in
terms of age, gender, hypertension, additive Euro score,
body mass index (BMI), baseline creatinine and surgery
type. A low ejection fraction (EF) was more notable in
the AKI group (Table 2). The AKI group had signifi-
cantly higher requirements for inotropes and vasopres-
sors. There were no significant differences between the
groups in terms of anesthesia time; however, CPB and
ACC were significantly higher in the AKI group
(Table 3).
The outcome variables, including the lengths of ventila-
tion, ICU and hospital stay, were significantly higher in
the AKI group. Post-operative complications, including
post-operative atrial fibrillation (POAF), hospital-mortality
and re-exploration, were significantly more frequent in
the AKI group. No significant differences in the incidence
of VAP and re-admission to the ICU were observed be-
tween groups. PMI was more frequent in patients with
PMI (Table 3). Finally, Table 4 illustrates the relation of
the outcome variables to HsTnT values.
Significant differences in hsTnT were observed between
the two groups (Fig. 1) throughout the study period. The
same changes were associated with CK-MB early in the
study period but not later in the study period (Fig. 2).
Discussion
The salient findings of this study were as follows: 1)
AKI patients exhibit changes in hsTnT but not CK-MB
after cardiac surgery injury; 2) high mortality and mor-
bidity were observed in the group with AKI in terms of
Table 1 Description of the studied group
Variable Number Minimum Maximum Mean ± SD
Age 359 18 75 57.2 ± 11.6
BMI (kg/m2) 358 17.1 46.9 28.1 ± 7.1
Creatinine (micromole/L) 359 54.1 178.7 97.1 ± 60.1
EF% 355 20 66 50.1 ± 10.1
Additive Euro score 354 0 18 3.6 ± 2.9
CPB time (minutes) 356 0 344 120.7 ± 56.3
ACC time (minutes) 356 0 180 86.1 ± 40.1
Anesthesia time (minutes) 355 200 648 301 ± 81
LOV (minutes) 354 210 4701 502 ± 481
LOShosp (days) 354 6 499 35.1 ± 30.6
BMI body mass index, EF ejection fraction, CPB cardiopulmonary bypass, ACC
aortic cross clamp, WBCs white blood cells, LOV length of mechanical
ventilation, LOShosp Hospital length of stay
Table 2 Demographic differences between both groups





Age 54.43 ± 10.8 56.09 ± 10.7 0.13
Gender (male) 222 (85.7) 83 (83) 0.34
Diabetes 138 (53.2) 56 (56) 0.38
Hypertension 124 (47.8) 59 (59) 0.13
Euro score 3.8 ± 2.4 5.1 ± 3.6 0.06
BMI 28.1 ± 5.8 28.9 ± 6.2 0.12
EF < 40 14 (5.4) 21 (21) 0.001
Elective surgery 165 (63.7) 57 (57) 0.065
Basal creatinine
(micromole/L)
88.2 ± 41.7 92.1 ± 42.3 0.6
Surgery
CABG 212 (82.4) 79 (79) 0.6
Valvular 30 (16) 18 (18) 0.7
Aortic disssection 4 (1.3) 1 (1)
BMI body mass index, EF ejection fraction, CABG coronary artery bypass graft
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POAF events and re-exploration; and 3) the AKI group
exhibited prolonged lengths of ventilation, ICU and
hospital stay. The utility of sensitive cardiac troponin
for the early diagnosis of acute cardiac events has
already been demonstrated [14]. The predictive value of
cardiac troponin for patient outcomes in ESRD has
been reported for a long time [5]. In addition, the inci-
dence of AKI and the potential impact on patients
undergoing cardiac surgery was elucidated in some pre-
vious studies [19]. Meanwhile, the impact of AKI on
cardiac troponins and their implications after cardiac
surgery have not yet been studied.
To our knowledge, this study is the first to evaluate
the diagnostic performance of hsTnT in the setting of
cardiac surgery-induced AKI. This study showed that
hsTnT may be an inaccurate marker of perioperative
myocardial infarction in those patients who develop AKI
post cardiac surgery. We showed that hsTnT is raised in
AKI patients independent of cardiac events. While a few
studies have addressed troponin in AKI [23], we are not
aware of any studies that investigated hsTnT.
Rosner and Okusa reported previously that the patho-
genesis of AKI associated with cardiac surgery involves
multiple pathways. These pathways include inflammatory,
hemodynamic, and nephrotoxic factors and may include
other factors that are involved and overlap with each
other, leading to kidney injury [24]. Risk factors for AKI
have been identified in some clinical trials, and these fac-
tors can be used to determine the risk for AKI in patients
who undergo cardiac surgery. The major risk factors in-
clude diabetes mellitus, hypertension, female gender, heart
failure and a low EF [24].
In our study cohort, we encountered AKI in 27.8% of
patients, which is within the range reported in the litera-
ture [24]. However, we believe that this value is relatively
high. This high percentage could be attributed to the
high incidence of diabetes mellitus, hypertension and
Table 3 Main differences in both studied groups






Dopamine 19 (7.3) 11 (11) 0.05
Adrenaline 12 (4.6) 14 (14) 0.05
Noradrenline 34 (13.1) 24 (24) 0.03
Dobutamine 2 (0.9) 2 (2) 0.7
Intraoperative parameters
CPB time (minutes) 119 ± 43 135 ± 69.6 0.06
ACC time (minutes) 77.1 ± 33 77.4 ± 48.5 0.09
Anesthesia time (minutes) 6.8 ± 1.4 6.7 ± 2 0.9
Postoperative parameters
LOV(minutes) 364.1 ± 112 575.5 ± 199 0.001
LOSICU (hours) 52.9 ± 41.1 109.4 ± 89 0.000
LOShosp (days) 10.1 ± 3.4 16.7 ± 4.7 0.001
Post-Operative outcome
POAF 7 (2.7) 12 (12) 0.005
Inhospital-mortality 3 (1.1) 5 (5) 0.03
VAP 5 (1.9) 2 (2) 0.8
Re-admission ICU 8 (3) 6 (6) 0.07
Re-exploration 24(6.5) 11 (26.8) 0.02
PMI 2 (0.8) 6 (6) 0.02
AKI acute kidney injury, CPB cardiopulmonary bypass, ACC aortic cross clamp,
LOV length of mechanical ventilation, LOSICU ICU length of stay, LOShosp
Hospital length of stay, POAF post-operative atrial fibrillation, VAP ventilator
associated pneumonia
Table 4 Outcome variables in relation to HsTnT
Beta coefficient Significance
AKI .47 0.001
peri op MI .91 0.013
LOSHOSP (days) .005 0.090




AKI acute kidney injury, PMI perioperative myocardial infarction, LOShosp
Hospital length of stay, LOV length of mechanical ventilation, POAF post-
operative atrial fibrillation
Linear multivariate analysis for troponin values
Fig. 1 Changes in hsTnT in both groups
Fig. 2 Changes in CK-MB in both groups
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low EF in the study group. These factors would expose
the patients to a higher risk of developing AKI.
Acute kidney injury is strongly associated with poor
outcomes in terms of morbidity and mortality—espe-
cially in the setting of cardiac surgery [24, 25]. In our
study, mortality and other outcome measures were sig-
nificantly higher in the AKI group than the non-AKI
group. Most outcome parameters were significantly
higher in the AKI group. The requirement for more ino-
tropic support, the length of ventilation (LOV), the
LOSICU and the LOSHosp were significantly elevated.
These findings are consistent with other clinical reports
in which high mortality and more complicated hospital
courses were encountered in patients who underwent
cardiac surgery and developed AKI.
Mao et al. performed a prospective, multicenter cohort
study of 1,219 patients and confirmed the relationship
with important clinical outcomes, including a longer
length of hospital and ICU stay and a higher risk of
dialysis or death [25]. However, the occurrence of AKI
could be a sensitive indicator of the severity of the peri-
operative insult and poor physiological reserves, as well
as a direct cause of the poor outcome [19]. Similarly we
found changes in the outcome variables with higher
levels of HsTnT (Table 4).
In patients with chronic kidney disease, it is possible
to have elevated cardiac troponins even in the absence
of true cardiac injury. This elevation could occur due to
different processes, including decreased clearance and
possible re-expression of cardiac troponin in uremic
myopathic skeletal muscles [2]. Meanwhile, several stud-
ies have reported that increased cardiac troponin in end-
stage renal disease patients is an independent predictor
of both short- and long-term mortality [5, 26].
In addition, elevated cardiac troponin levels in AKI
patients post-cardiac surgery result in different effects,
including myocardial cell injury due to incomplete car-
dioprotection, direct surgical trauma and possible re-
perfusion injury. This observation does not reflect
perioperative myocardial infarction [2]. Here, we found
that significant POAF events were associated with the
AKI group. This association was also reported in a re-
cent study by Kristovic et al. [27].
In our study cohort, we demonstrated a persistent rise
in cardiac hsTnT in the AKI group across the entire time
course. This pattern was not observed for the CK-MB
marker. This trend of rising hsTnT in the setting of AKI
should be considered when evaluating the diagnostic per-
formance of hsTnT in patients with recent cardiac surgery
for a cardiac insult—especially in the absence of a clear
hsTnT diagnostic discrimination point. Omar et al. de-
fined values (3,466 ng/L and 2,309 ng/L) for hsTnT that
accompany PMI and myocardial injury, respectively [28].
We found that PMI events were significantly more
frequent in patients with AKI (Table 3), PMI was associ-
ated with high levels of HsTnT (Table 4). Perhaps when
AKI develops after cardiac surgery, the biochemical diag-
nosis of a new cardiac insult using cardiac hsTnT should
be based on a rising trend rather than a parallel rise or a
defined value while keeping in mind the expected rise in
hsTnT throughout the AKI course.
Study strengths, limitations and recommendations:
To our knowledge, this study is the first study to de-
scribe hsTnT changes in the setting of AKI. However,
the findings should be interpreted with some caution.
We recognize some limitations of our study, such as the
short follow-up period, the retrospective design, and the
lack of cut-off values for CK-MB and hsTnT, as well as
the lack of a correlation with creatinine levels. The study
was conducted in one center, and long-term follow up of
the patients was impossible due to the highly dynamic
work conditions in Qatar. These limitations could be
further addressed in future studies.
Conclusion
Unlike the CK-MB assay, hsTnT exhibited significant
changes in the AKI group, suggesting possible delayed
clearance. A rise in hsTnT should be interpreted cau-
tiously as a marker of post-operative myocardial injury
and infarction in patients with AKI.
Abbreviation
ACC: Aortic cross clamp; AKI: Acute kidney injury; AMI: Acute myocardial
infarction; CK-MB: Creatine kinase MB; CPP: Cardiopulmonary bypass time;
EF: Ejection fraction; ESRD: End stage renal disease; hsTntT: High sensitive
troponin T; ICU: Intenzsive care unit; LOSHosp: Length of stay in hospital stay;
LOSICU: Length of stay in ICU; LOV: Length of ventilation; PMI: Perioperative
myocardial infarction; POAF: Post-operative atrial fibrillation
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